Clinical efficacy and safety of Liraglutide in the treatment of obese or overweight patients with different duration of T2DM

杜益君,潘天荣,钟兴,刘妮娜,张萍

DOI: https://doi.org/10.3969/j.issn.1006-6187.2015.12.003

2015-01-01

Abstract:Objective To assess the clinical efficacy and safety of Liraglutide in the treatment of obese or overweight patients with different duration of type 2 diabetes (T2DM ). Methods A total of 78 obese or overweight T2DM patients in poor glycemic control by oral antidiabetics (OADs) were selected and divided into two groups :short duration group (≤5 years ,n=39) and long duration group (>5 years , n=39). Patients in both groups were treated with Liraglutide on the basis of original treatment regimen for 14 weeks. Clinical efficacy and adverse reactions were compared between two groups. Results HbA1c ,FPG ,2 hPG and BMI of both groups significantly decreased and homeostatic model islet β-cell function index (HOMA-β) significantly increased after treatment with Liraglutide ( P < 0.01 ). Homeostatic model insulin resistance index (HOM A-IR) significantly decreased and insulin sensitive index (ISI) significantly increased in short duration group after treatment with Liraglutide (P< 0.01).The&nbsp;decrease of HbA1c ,FPG and HOMA-IR and the increase of HOMA-βin short duration group were more obvious than in long duration group (P<0.01). There was no significant difference in the incidence of hypoglycemia(P>0.05) .Severe hypoglycemia events were not observed in both groups. Conclusion Liraglutide can decrease blood glucose ,reduce body weight and improve the function of islet βcell in obese or overweight patients with different duration of T 2DM. The efficacy of Liraglutide was more significant w hen used at early stage of T 2DM.